CHMFL-ALK/EGFR-050 showed potent anti-tumor activity in pre-clinical NSCLC models driven by either mutant EGFR or ALK [91], but whether or not it will be suitable for NSCLC patients and a less toxic alternative for patients with dual ALK/EGFR overactivity, remains to be determined. Here, ALK is linked to neoplasm.